✦ LIBER ✦

Efficacy and safety of deferasirox in myelodysplastic syndromes

✍ Scribed by Massimo Breccia, Giuliana Alimena

Book ID: 120775767
Publisher: Springer
Year: 2013
Tongue: English
Weight: 160 KB
Volume: 92
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-013-1703-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Results from a 1-year, open-label, singl

Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload

✍ Nolte, F.; HÃ¶chsmann, B.; Giagounidis, A.; LÃ¼bbert, M.; Platzbecker, U.; Haase 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 215 KB

Deferasirox treatment for myelodysplasti

Deferasirox treatment for myelodysplastic syndromes: “real-life” efficacy and safety in a single-institution patient population

✍ Breccia, Massimo; Finsinger, Paola; Loglisci, Giuseppina; Federico, Vincenzo; Sa 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 135 KB

Long-term efficacy and safety of deferas

Long-term efficacy and safety of deferasirox

✍ Maria Domenica Cappellini 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 117 KB

Deferasirox is an oral iron chelator, with a long half-life, that can be given once daily, because it provides a 24-hour chelation. Several phase II trials and a pivotal phase III trial have established that, in transfusion-dependent patients with beta-thalassaemia major, deferasirox has a similar e

Deferasirox induces regression of iron o

Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes

✍ F. Wimazal; T. Nösslinger; C. Baumgartner; W. R. Sperr; M. Pfeilstöcker; P. Vale 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB

FLAG regimen shows efficacy in myelodysp

FLAG regimen shows efficacy in myelodysplastic syndromes

📂 Article 📅 2000 🏛 Adis International Limited (now part of Wolters Kl ⚖ 138 KB

Safety and Efficacy of Romiplostim in Pa

Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia

✍ Kantarjian, H.; Fenaux, P.; Sekeres, M. A.; Becker, P. S.; Boruchov, A.; Bowen, 📂 Article 📅 2010 🏛 American Society of Clinical Oncology 🌐 English ⚖ 281 KB